Around 7.4 million women took Bravelle® (a popular fertility drug) to get rid of infertility problems. Many couples and individuals underwent this infertility treatment method with the hope of becoming fertile. Their expectation was that they would become fertile as the consequence of the strong effect of this fertility drug.
Unfortunately, in October 2015, Ferring Pharmaceuticals, the manufacturer of Bravelle®, found that the potency of several batches of Bravelle® was reduced. Consequently, the drug had failed to fulfill the expectation of many prospective parents. The manufacturing company decided to voluntarily recall and withdraw these drugs from the market. Subsequently, this Swiss drug-maker, Ferring Pharmaceuticals issued letters to the users who used Bravelle® between March 2014 and October 2015, promising them to reimburse or repay the drug’s price. The company has already started a reimbursement program for anyone who purchased the drug between those dates. They are trying to withdraw the remaining drugs from the market as soon as possible.
Bravelle® lawsuits started as a result of this information. Many users of this fertility drug, who purchased it between March 2014 and October 2015, filed lawsuits against Ferring Pharmaceuticals, based on the grounds that the Switzerland-based Pharmaceutical Company had failed to warn them before. As the consequence of this failure users have suffered emotionally, physically and financially. They have filed Bravelle® lawsuits, claiming compensation for losses and damages. Many new users have started doing the same with an effort to recover their losses.
Bravelle® lawsuits claim that the manufacturing company has failed to warn the consumers about the fact that some of the Bravelle® batches were not working. The litigations demand compensation as Ferring Pharmaceuticals did not provide any reliable way to inform people whether they were purchasing drugs from the recalled lots.
A recent lawsuit has been filed against Ferring Pharmaceuticals in April 2018 in the U.S. District Court for the Eastern District of New York. In this lawsuit, a New York couple, Angela and Daniel Lauruska, claimed that they have spent between $20,000 and $30,000 for a round of in-vitro fertilization and received no significant result as the consequence of a defective Bravelle® injection.